Is Retatrutide FDA Approved? Status and Release Date (2026)

The Short Answer

No, retatrutide is not approved. As of October 31, 2026, no regulatory authority in the world has approved retatrutide. That includes the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) and every other national regulator. It is still an investigational compound in Phase 3 clinical development. It has no brand name, is not available by prescription, and cannot legally be bought from any pharmacy or licensed distributor.

People ask this a lot because of media coverage of five positive Phase 3 readouts in 2025-2026: TRIUMPH-4 (December 2025, -28.7% weight loss at 12 mg in obesity with knee OA), TRANSCEND-T2D-1 (published in The Lancet June 6, 2026: HbA1c -1.9 points and -15.3% weight loss at 12 mg in type 2 diabetes), TRIUMPH-1 (May 21, 2026, -28.3% at 12 mg over 80 weeks in 2,339 adults with obesity but no diabetes), and on July 23, 2026 TRIUMPH-2 (-20.8% in obesity with type 2 diabetes) and TRIUMPH-3 (-22.6% in severe obesity with cardiovascular disease). Even with the pivotal program complete, approval still needs a regulatory submission and FDA review. Eli Lilly has said it plans to file its application no later than the first quarter of 2027; nothing has been filed yet.

Why Is Retatrutide Not Yet Approved?

The Drug Development Process

It helps to know the standard path a drug takes. In the United States, the FDA requires new drugs to go through a series of clinical phases before they can be considered for approval:

• Phase 1: Small studies in healthy volunteers or patients to assess safety, tolerability, and pharmacokinetics. Retatrutide completed Phase 1 studies.
• Phase 2: Moderate-sized studies to evaluate efficacy, determine optimal dosing, and further characterize safety. Retatrutide completed Phase 2 studies with positive results published in the New England Journal of Medicine (obesity) and The Lancet (type 2 diabetes).
• Phase 3: Large, pivotal studies involving thousands of participants designed to confirm efficacy, establish the safety profile in a broader population, and generate the data required for regulatory submission. Retatrutide is currently in this phase.
• Regulatory review: After Phase 3 completion, the sponsor (Eli Lilly) submits a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA, which then reviews the complete data package and decides whether to approve the drug.

Retatrutide has now completed its pivotal Phase 3 program: TRIUMPH-1, -2, -3 and -4 and TRANSCEND-T2D-1 have all reported positive results. No application has been filed yet. Eli Lilly stated on July 23, 2026 that it plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain, and on August 5, 2026 that the clinical data package is complete and the remaining work is manufacturing (CMC) data. The July plan for a BLA rather than an NDA reflected Lilly’s view that the peptide (a 39-amino-acid chain with a fatty-acid side chain, which Lilly counts as 41 units) is a biologic. On October 2, 2026 the FDA ruled that retatrutide is a drug, not a biologic, so the application must be a New Drug Application (NDA). Lilly is challenging the FDA ruling in court, its appeal (Eli Lilly v. Kennedy, Seventh Circuit) has not been decided, and it has not said which pathway it will use. Lilly’s most recent statement (October 8, 2026) is that it plans to file no later than the first quarter of 2027.

What Phase 3 Must Demonstrate

Before a regulatory submission can go ahead, the Phase 3 program has to do several things:

• Confirm efficacy in large, diverse patient populations for each intended indication (obesity, type 2 diabetes, and potentially MASH)
• Establish the safety profile with enough statistical power to detect uncommon adverse events, including characterizing the dysesthesia signal found in TRIUMPH-4
• Characterize long-term effects over treatment durations longer than the 48 weeks studied in Phase 2
• Identify the optimal dose and escalation regimen for clinical use
• Evaluate effects in special populations including older adults, patients with renal impairment, and patients with cardiovascular disease

What “Phase 3” Means for Patients

Phase 3 is the last stage of clinical development before a regulatory submission. Being in Phase 3 means:

• The drug has shown promise: Phase 2 data were good enough to justify the heavy investment in a large Phase 3 program
• Large-scale testing is underway: Thousands of participants are being treated in many countries and clinical sites
• Approval is not guaranteed: Historically, about 50-60% of drugs that enter Phase 3 end up with FDA approval. Positive Phase 3 results raise the odds a lot, but unexpected safety problems, weak efficacy or manufacturing issues can still block approval
• The timeline can be measured: Unlike earlier stages, Phase 3 trials have set endpoints and estimated completion dates, so timeline projections are more reliable

For patients, Phase 3 status means the drug is moving forward but is still years from commercial availability.

The TRIUMPH Phase 3 Program

Program Overview

Eli Lilly’s Phase 3 clinical program for retatrutide is called TRIUMPH. It is one of the largest metabolic drug programs now underway, with several clinical trials testing retatrutide across different indications and patient groups:

• TRIUMPH-1 through TRIUMPH-4: Four pivotal trials evaluating retatrutide for obesity and weight-related conditions
• TRIUMPH-Outcomes: ~10,000-patient cardiovascular outcomes trial (CVOT)
• TRANSCEND: Type 2 diabetes program (TRANSCEND-T2D-1, TRANSCEND-T2D-2 head-to-head vs semaglutide, and TRANSCEND-CKD)
• SYNERGY / MACELD: Trials for metabolic dysfunction-associated steatohepatitis (MASH), with histological endpoints

TRIUMPH-4: First Phase 3 Results (December 2025)

TRIUMPH-4 was the first trial in the program to report results. It enrolled 445 adults with obesity and knee osteoarthritis and showed:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 9 mg: -26.4% mean weight loss at the same timepoint
• 99% of participants at 12 mg achieved at least 5% weight loss
• 75% reduction in knee osteoarthritis pain scores
• New safety finding: dysesthesia (numbness, tingling, burning sensations) in 20.9% at 12 mg versus 0.7% placebo

TRANSCEND-T2D-1 (March 19, 2026)

Positive topline results were announced in an Eli Lilly press release on March 19, 2026 and discussed further on the Q1 2026 earnings call on April 30:

• HbA1c reductions of 1.7-2.0 percentage points across doses, blood sugar control comparable to tirzepatide
• Weight loss of 11.5-16.8% across doses (n=537, 40 weeks; topline figures; the paper published in The Lancet on June 6, 2026 reports 1.69-1.94 points and 11.5-15.3%)
• Dysesthesia 2.3-4.5% across doses (lower than the obesity trials)
• Management presented the mix of blood sugar control plus extra weight loss as what sets retatrutide apart from tirzepatide in people with T2D

TRIUMPH-1: Pivotal Obesity Trial (May 21, 2026)

The largest readout so far, and the anchor trial for the obesity indication:

• Retatrutide 12 mg: -28.3% mean weight loss (efficacy estimand) at 80 weeks in 2,339 adults with obesity but no diabetes
• 45.3% of 12 mg participants achieved ≥30% weight loss, a level usually associated with bariatric surgery
• 65.3% ended the trial with BMI <30 (no longer obese)
• All three doses (4 mg, 9 mg, 12 mg) met the primary endpoint
• 104-week extension hit -30.3% in the BMI ≥35 subgroup
• Dysesthesia at 12 mg: 12.5%, well below TRIUMPH-4’s 20.9% at the same dose
• Discontinuation due to AEs at 12 mg: 11.3%, also lower than TRIUMPH-4’s 18.2%

Remaining Trials

On July 23, 2026 Eli Lilly reported the final two pivotal obesity trials. TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes, 80 weeks) showed -20.8% mean weight loss at 12 mg versus -4.0% on placebo, with A1C reductions of 1.4 to 1.6 points. TRIUMPH-3 (1,949 adults with BMI 35 or higher and established cardiovascular disease, 80 weeks) showed -22.6% at 12 mg versus -3.2%. Dysesthesia at 12 mg was 7.3% and 6.4% respectively, well below the 20.9% seen in TRIUMPH-4. Details: TRIUMPH-2 and TRIUMPH-3 results. The head-to-head TRANSCEND-T2D-2 trial against semaglutide 2 mg reported topline results on October 28, 2026 (not yet peer reviewed). The TRIUMPH-Outcomes cardiovascular outcomes trial and the SYNERGY/MACELD MASH trials run on longer timelines and are not needed for the first obesity submission.

Expected Timeline for Approval

Realistic Projections

Based on where the TRIUMPH program stands:

These projections are quite uncertain. Enrollment delays, unexpected safety findings, FDA requests for more data or manufacturing problems could all push the timeline back. On the other hand, breakthrough therapy designation or a rolling submission could shorten it.

Comparison to Tirzepatide’s Timeline

Eli Lilly’s tirzepatide (Mounjaro/Zepbound) is a useful comparison:

• SURMOUNT-1 Phase 3 obesity data published: mid-2022
• Zepbound FDA approval for obesity: November 2023
• Time from Phase 3 data to obesity approval: approximately 17 months

But tirzepatide already had a diabetes approval (Mounjaro, May 2022), which gave it an established safety database. Retatrutide lacks that advantage, as it has never been approved for anything.

FDA Review Process

Once Eli Lilly submits its application, FDA review follows set steps:

• 60-day filing review: FDA determines if the application is complete enough to accept
• Standard Review: 10-12 months from acceptance to decision
• Priority Review: 6-8 months, granted when the drug offers significant improvement over existing treatments
• Advisory Committee: The FDA may call in outside experts to weigh benefits and risks, especially given the new triple receptor mechanism and the dysesthesia signal

How to Access Retatrutide Today

Clinical Trials Are the Only Legitimate Route

The only way to receive retatrutide is through an authorized clinical trial. To explore this option:

1. Visit ClinicalTrials.gov and search for “retatrutide” or “LY3437943”
2. Review the list of active trials and their eligibility criteria
3. Discuss potential participation with your healthcare provider
4. Contact the study sites listed for trials that may be appropriate

Trial participation has its own trade-offs: randomization (you may get placebo), strict visit schedules, monitoring, and eligibility criteria that may exclude many people.

What Clinical Trial Participation Involves

Participants in TRIUMPH trials typically go through:

• Screening assessments to verify eligibility
• Regular clinic visits (often monthly) for injections, lab work, and assessments
• Possibility of receiving placebo rather than active drug
• Long treatment periods (68+ weeks for most pivotal trials)
• Follow-up after treatment completion

Warning About Illegitimate Sources

The Problem of Gray-Market Peptides

High public interest in retatrutide has created a market for unregulated peptide products claiming to be retatrutide. They are sold by various online sources, including research chemical suppliers, compounding pharmacies working outside normal regulatory oversight, and international vendors. These products carry significant risks:

• No quality assurance: Unregulated products are not made under Good Manufacturing Practice (GMP) conditions. Nothing guarantees their purity, potency, sterility or even identity. Independent analyses of gray-market peptides have repeatedly found contamination, wrong potency and mislabeling.
• Unknown safety: Without manufacturing controls, these products may contain impurities, endotoxins or degradation products that are harmful in their own right, apart from the active peptide.
• No medical supervision: People using unregulated products usually do so without dose titration or safety monitoring. That is especially worrying for a triple receptor agonist that affects glucose metabolism, heart rate and the gut, and that has shown dysesthesia rates of 6-21% at the 12 mg dose across the Phase 3 obesity trials (highest in TRIUMPH-4).
• Legal concerns: Selling unapproved drug products is illegal in many jurisdictions. Products shipped internationally may be seized at customs.

Compounding Pharmacy Warning

Semaglutide and tirzepatide were at times on FDA drug shortage lists, which temporarily allowed some compounding. Retatrutide has never been approved and therefore is not listed in any drug shortage database. Compounding pharmacies that make products labeled as retatrutide are working entirely outside the regulatory framework.

No compounding pharmacy has a legitimate basis to make retatrutide. Any such product:

• Is not FDA-approved or FDA-regulated
• Has not been tested for safety, purity, or efficacy
• May not contain retatrutide at all, or may contain incorrect quantities
• Carries unknown impurity and contamination risks

Our Recommendation

We do not endorse or encourage using retatrutide from any source other than authorized clinical trials. The risks and benefits of an investigational drug can only be properly judged within a clinical trial, where participants get properly made drug, receive appropriate screening and monitoring, and contribute to the data that will eventually inform regulatory decisions.

What Should Patients Do Now?

While waiting to see whether retatrutide becomes available, you have several options for effective weight management:

• FDA-approved medications: Semaglutide (Wegovy), tirzepatide (Zepbound), and other approved anti-obesity medications are available by prescription
• Clinical trials: Beyond retatrutide, many obesity clinical trials are enrolling participants for various investigational treatments
• Broader care: Behavioral modification, dietary counseling, and exercise programs remain the foundation of weight management
• Discuss with your provider: Healthcare professionals can help build a treatment plan from currently available options while you keep an eye on retatrutide’s progress

Frequently Asked Questions

Can my doctor prescribe retatrutide?

No. Because retatrutide is not approved, it cannot be prescribed. It is available only through authorized clinical trials.

When will retatrutide be available?

The earliest realistic date is late 2027 if the FDA grants Priority Review, and more likely around the first quarter of 2028 under standard review (our estimates), based on Eli Lilly’s plan to file no later than Q1 2027. Commercial launch would follow approval. This timeline could change depending on the FDA’s filing decision and review.

Is retatrutide the same as tirzepatide?

No. Both are incretin-based peptide drugs developed by Eli Lilly, but they are different molecules. Tirzepatide (sold as Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that is approved and on the market. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist that is still investigational.

Are the peptides sold online legitimate?

Products sold as retatrutide outside clinical trials are not approved medicines. No one can vouch for their quality, purity or safety, and using them carries significant risks. There is no FDA drug shortage designation for retatrutide, so compounding pharmacies have no regulatory basis to make it.

Did TRIUMPH-4 results mean approval is coming soon?

TRIUMPH-4 showed impressive efficacy (-28.7% weight loss), but one Phase 3 trial was never going to be enough. The full program has since reported (TRIUMPH-1 in May 2026, TRIUMPH-2 and TRIUMPH-3 in July 2026), and Eli Lilly plans to file for approval no later than Q1 2027. On our estimate, approval could come as early as late 2027 with Priority Review, or around the first quarter of 2028 under standard review.

The FDA Regulatory Pathway in Detail

Marketing Application Requirements

For retatrutide to win FDA approval, Eli Lilly must submit a marketing application with full data on the drug’s chemistry, manufacturing, and controls (CMC); nonclinical pharmacology and toxicology; clinical pharmacology and pharmacokinetics; and clinical efficacy and safety from the Phase 3 pivotal trials. Lilly has argued that retatrutide should be regulated as a biologic, which would make the application a Biologics License Application (BLA) rather than a New Drug Application (NDA). The distinction matters commercially: a biologic receives 12 years of data exclusivity rather than five and is outside the pharmacy-compounding provisions that apply to drugs. The FDA has disputed whether the peptide (a 39-amino-acid chain that Lilly counts as 41 units) meets the legal definition of a protein. A district court sided partly with each side, and Lilly’s appeal (Eli Lilly v. Kennedy) was argued before the Seventh Circuit on September 24, 2026; the parties filed memoranda on October 8, 2026, and there is no ruling as of October 31, 2026. The FDA has since ruled (October 2, 2026) that retatrutide is a drug, so the application must be an NDA; Lilly disputes that in court and has not said which pathway it will use. Whichever application type is used, the data package must show that retatrutide is safe and effective for its proposed uses and that its benefits outweigh its risks.

Obesity Indication

For approval as an anti-obesity medicine, the FDA’s guidance (Developing Products for Weight Management, 2007) requires a drug to show one of the following:

• A statistically significant difference in mean weight loss from baseline compared to placebo, with the active treatment group achieving at least 5% mean weight loss
• A statistically significant difference in the proportion of participants achieving at least 5% weight loss, with at least 35% of the active treatment group reaching this threshold and approximately double the rate in the placebo group

Based on Phase 2 data, retatrutide clears these thresholds easily, and the Phase 3 readouts have backed this up, including these two. TRIUMPH-4 (December 2025), a 68-week study in 445 adults with obesity and knee osteoarthritis, reported 28.7% mean weight loss at 12 mg and 26.4% at 9 mg, with all primary and key secondary endpoints met. TRIUMPH-1 (May 21, 2026), the pivotal obesity trial in 2,339 adults without diabetes, reported 28.3% mean weight loss at 12 mg over 80 weeks (efficacy estimand), with all three doses (4 mg / 9 mg / 12 mg) meeting primary endpoints. The dysesthesia rate at 12 mg in TRIUMPH-1 was 12.5%, well below the 20.9% reported in TRIUMPH-4 at the same dose, likely because the TRIUMPH-1 population had fewer other health conditions. The 104-week extension showed weight loss continuing to -30.3% in the BMI ≥35 subgroup.

Type 2 Diabetes Indication

For approval as a type 2 diabetes treatment, the FDA requires a clinically meaningful improvement in blood sugar control, usually measured as a drop in HbA1c from baseline compared with placebo or an active comparator. The TRANSCEND-T2D-1 trial reported positive topline results on March 19, 2026 (Eli Lilly press release): HbA1c reductions of 1.7-2.0 percentage points and weight loss of 11.1-16.6 kg across doses, which is blood sugar control comparable to tirzepatide plus extra weight loss. TRIUMPH-2 (obesity + type 2 diabetes), which covers both indications in a single trial, reported on July 23, 2026: -20.8% weight loss and an A1C reduction of 1.5 points at 12 mg over 80 weeks.

Cardiovascular Safety

From 2008 to 2020 the FDA asked makers of diabetes drugs to rule out excess cardiovascular risk (an upper bound of the 95% confidence interval for major adverse cardiovascular events below 1.8 before approval and 1.3 after). The FDA withdrew that guidance in 2020; its replacement asks instead for a large, long enough safety database. Retatrutide’s cardiovascular question is being answered directly by TRIUMPH-Outcomes, a cardiovascular outcomes trial of about 10,000 people that is still running.

Expedited Pathways

Retatrutide may qualify for one or more FDA expedited review pathways:

• Fast Track Designation: Available for drugs that treat serious conditions and fill an unmet medical need. Given how serious obesity is and how effective retatrutide may be, Fast Track designation is plausible.
• Breakthrough Therapy Designation: Available for drugs that show substantial improvement over existing therapies based on early clinical evidence. The Phase 2 weight loss data could support a Breakthrough Therapy application, though it is not publicly confirmed whether Eli Lilly has sought or received this designation for retatrutide.
• Priority Review: Available for drugs that offer significant improvements in treatment, safety, or effectiveness. If granted, Priority Review cuts the FDA’s review target from 10 months to 6 months.

Approval Outside the US

European Medicines Agency (EMA)

In Europe, approval goes through the EMA’s centralized procedure, which gives a marketing authorization valid in all EU member states. Eli Lilly would submit a Marketing Authorisation Application (MAA) based on the same Phase 3 data package used for the FDA, plus any Europe-specific requirements. The EMA’s Committee for Medicinal Products for Human Use (CHMP) reviews the application and issues an opinion, which the European Commission then adopts.

European approval usually comes 6-12 months after FDA approval, because the processes and review timelines differ.

Other Markets

Submissions in other major markets, including Japan (PMDA), China (NMPA), Canada (Health Canada) and Australia (TGA), would follow each agency’s own requirements. Eli Lilly usually staggers submissions across major markets after the first FDA approval.

Regulatory Considerations for MASLD

The liver fat reduction seen in Phase 2 trials has raised the possibility of developing retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD) or its more severe form, metabolic dysfunction-associated steatohepatitis (MASH). The regulatory path for MASLD/MASH drugs is different from obesity and diabetes:

• The FDA has accepted conditional approval pathways based on histological endpoints (resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis)
• A separate clinical trial program with liver biopsy endpoints would be required
• The first MASH therapy (resmetirom) received FDA accelerated approval in 2024, setting a regulatory precedent

Eli Lilly is actively pursuing a MASLD/MASH indication for retatrutide. The SYNERGY trial is testing retatrutide for MASH with histological endpoints, and the MACELD trial is also underway. Both trials are running as of October 2026.

Post-Marketing Requirements

If approved, retatrutide would face ongoing regulatory obligations:

• Risk Evaluation and Mitigation Strategy (REMS): Depending on the safety profile, the FDA may require a REMS program to ensure that the benefits outweigh the risks
• Post-marketing safety surveillance: Mandatory reporting of adverse events observed in clinical practice
• Post-marketing studies: The FDA may require additional studies to evaluate long-term safety, use in specific populations, or cardiovascular outcomes
• Label updates: The prescribing information would be updated as new safety and efficacy data emerge

Summary

Retatrutide is not approved by any regulatory authority as of October 2026. Its pivotal Phase 3 program is complete, with five positive readouts (TRIUMPH-4, TRANSCEND-T2D-1, TRIUMPH-1, TRIUMPH-2, TRIUMPH-3). Eli Lilly plans to file for approval no later than Q1 2027, with a possible FDA decision, on our estimate, in late 2027 (Priority Review) or around Q1 2028 (standard review). The FDA has ruled that the application must be an NDA; Lilly disputes that in court.

There is no legitimate commercial source for retatrutide. Outside clinical trials, the only sanctioned route is Lilly’s narrow expanded access program for adults with severe, refractory obesity, which a treating physician must request. If you are interested in retatrutide, check ClinicalTrials.gov for trial openings, talk to your healthcare provider about currently approved treatments, and avoid unregulated sources, which carry serious safety and quality risks. The FDA has issued multiple warning letters to compounders trying to sell unapproved retatrutide; retatrutide does not qualify for 503A or 503B compounding exemptions.